Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2016 by Roswell Park Cancer Institute
Sponsor:
Collaborator:
Novartis
Information provided by (Responsible Party):
Roswell Park Cancer Institute
ClinicalTrials.gov Identifier:
NCT01032148
First received: December 14, 2009
Last updated: March 1, 2016
Last verified: March 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: September 2017
  Estimated Primary Completion Date: September 2017 (Final data collection date for primary outcome measure)